Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass Y. Lamarche, MD, O. Malo, MSc, E. Thorin,

Slides:

Advertisements

Similar presentations

Urokinase treatment preserves endothelial and smooth muscle function in experimental acute arterial thrombosis David Whitley, MD, Peter Gloviczki, MD,

Advertisements

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Manuel J. Antunes, MD, PhD, DSc

Endothelial nitric oxide synthase enhancer for protection of endothelial function from asymmetric dimethylarginine–induced injury in human internal thoracic.

Minimizing intraoperative hemodilution by use of a very low priming volume cardiopulmonary bypass in neonates with transposition of the great arteries

Right internal thoracic artery or saphenous vein grafting

Derrick Y. Tam, MD, Stephen E. Fremes, MD, MSc, FRCSC, FACP, FACC

Intrinsic cardiac stem cells are essential for regeneration

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Abracadabra I, II…HeartMate 3?

Form ever follows function

Victor van Berkel, MD, PhD

William M. DeCampli, MD, PhD

Multilevel data analysis: What? Why? How?

Definition of postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass: One size doesn't fit all David Faraoni, MD,

Harold L. Lazar, MD The Journal of Thoracic and Cardiovascular Surgery

Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement Ole Lund, MD, PhD, Martin Bland,

The lord of the rings Antonio Miceli, MD, PhD

Hypogammaglobulinemia after cardiopulmonary bypass in infants

Surgical economics: MACRA, MIPS, and bundles—Lessons learned in the first 3 years of a coronary artery bypass grafting alternative payment model Daniel.

Conduit conundrum: If not two, why three?

The variability of the mitral valve anatomy and terminology

Main stem bronchus surgery with pulmonary preservation

Support Your Specialty

Innovation and science: The future of valve design

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

It's not “just a shunt” but sometimes it should be…

Military surgeons just want to have fun

A first start for lung transplantation?

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Chronic obstructive pulmonary disease severity influences outcomes after off-pump coronary artery bypass Benjamin Medalion, MD, Michael G. Katz, MD,

Derrick Y. Tam, MD, Stephen E. Fremes, MD, MSc

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

David L. Joyce, MD The Journal of Thoracic and Cardiovascular Surgery

Hisato Takagi, MD, PhD, Takuya Umemoto, MD, PhD

A fate worse than death Jennifer S. Lawton, MD

Attachment disorder in thoracoabdominal surgery

Commentary: Do the right thing! Ethical versus legal

Taking UP the chronic pulmonary obstructive disease gauntlet

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Using bilateral internal thoracic arteries—just do it

The thoracoabdominal saga and heroes

Shunt right or left? Decision 2016

Functional tricuspid pathology: To treat or not to treat

The harder one looks, the more one finds

Innovation in cardiothoracic surgical training

First nights, the adrenal axis, and steroids

The origins of open heart surgery at the University of Minnesota 1951 to 1956 Richard A. DeWall, MD The Journal of Thoracic and Cardiovascular Surgery

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Keep it short and sweet Ian A. Makey, MD, Scott B. Johnson, MD

The future of cardiac surgery training: A survival guide

The continuing challenge of congenital heart disease in China

Ralph E. Delius, MD The Journal of Thoracic and Cardiovascular Surgery

After neoadjuvant chemoradiation therapy, predicted pulmonary function may be reduced by 10% Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular.

“The more things change…”: The challenges ahead

Apples remain apples NO matter what

Energized lung resections

Respect the aorta The Journal of Thoracic and Cardiovascular Surgery

Preoperative PFTs: The answer is blowing in the wind

Sunjay Kaushal, MD, PhD, Brody Wehman, MD

Did you like Terminator 3 better than Terminator 2

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Carl L. Backer, MD, Bradley S. Marino, MD, MPP, MSCE

Journal changes and initiatives

Edward Y. Chan, MD, Michael J. Reardon, MD

Akiko Tanaka, MD, PhD, Takeyoshi Ota, MD, PhD

Commentary: Radial artery and bilateral mammary arteries in coronary artery bypass grafting: How much is too much? Derrick Y. Tam, MD, Stephen E. Fremes,

Deciding how much to pay for effective care

Presentation transcript:

Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass Y. Lamarche, MD, O. Malo, MSc, E. Thorin, PhD, A. Denault, MD, M. Carrier, MD, MSc, J. Roy, CPP, L.P. Perrault, MD, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 130, Issue 1, Pages 83-92 (July 2005) DOI: 10.1016/j.jtcvs.2004.09.011 Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 A, Rings of porcine pulmonary with endothelium. X-axis, Log acetylcholine (mol/L); Y-axis, tension (percent contraction to phenylephrine); PE, phenylephrine. Data are expressed as means ± SEM. *P < .05, CPB versus inhaled milrinone; **P < .01, CPB versus inhaled milrinone; ***P < .001, CPB versus inhaled milrinone; +P < .05, inhaled versus intravenous milrinone; ++P < .01, inhaled versus intravenous milrinone; ¶P < .05, control versus CPB; ¶¶P < .01, control versus CPB; ¶¶¶P < .001, control versus CPB; †P < .05, control versus intravenous milrinone; ‡P < .05, control versus intravenous milrinone. B, Rings of porcine pulmonary with endothelium. X-axis, Log bradykinin (mol/L); Y-axis, tension (percent contraction to phenylephrine); PE, phenylephrine. Data are expressed as means ± SEM. *P < .05, CPB versus inhaled milrinone; **P < .01, CPB versus inhaled milrinone; +P < .05, inhaled versus intravenous milrinone; ++P < .01, inhaled versus intravenous milrinone; +++P < .001, inhaled versus intravenous milrinone; #P < .05, CPB versus intravenous milrinone; ##P < .01, CPB versus intravenous milrinone; ¶P < .05, control versus CPB; /P < .05, control versus inhaled milrinone; //P < .01, control versus inhaled milrinone; ///P < .001, control versus inhaled milrinone; †P < .05, control versus intravenous milrinone; ‡P < .01, control versus intravenous milrinone; †††P < .001, control versus intravenous milrinone. The Journal of Thoracic and Cardiovascular Surgery 2005 130, 83-92DOI: (10.1016/j.jtcvs.2004.09.011) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Concentration of cAMP in pulmonary arteries after CPB. X-axis, Study groups; Y-axis, cAMP concentration (pmol/mg proteins). Data are expressed as means ± SEM. *P < .05 versus CPB; +P < .05 versus inhaled milrinone; ¶P < .05 versus control. The Journal of Thoracic and Cardiovascular Surgery 2005 130, 83-92DOI: (10.1016/j.jtcvs.2004.09.011) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions